Category: FDA & Regulatory Policy (Page 6)

May 15, 2015

ACT-AD Letter to DeGette and Upton Re: 21st Century Cures

This letter is from the ACT-AD Coalition to Rep. Fred Upton and Rep. Diana DeGette applauding their work around the 21st Century Cures bill.
May 11, 2015

Webinar: Targets for the Next Generation of Alzheimer’s Disease Treatment

On April 27 the Alliance's ACT-AD Coalition held a webinar on the future of research, therapeutic development, and treatment of Alzheimer’s disease.
March 10, 2015

Infographic on Pain Incidence and Management

Today we released a survey of 1,600 Americans ages 18 and over that reveals insights on pain and OTC pain medications. This infographic offers a summary of the results.
March 9, 2015

New Survey Shows Americans Prefer Education Over Restricted Access When It Comes to OTC Pain Medications

Results Also Reveal Many Older Adults Use OTC Medications to Relieve Pain
March 4, 2015

Alliance Offers Comment on FDA Testosterone Prescription Labeling Communication

We wanted to share our reaction to communication from the U.S. Food and Drug Administration regarding updates to the labeling of prescription testosterone products.
February 12, 2015

Matching the Needs of Patients with Those of Our Federal Health Agencies

On Tuesday, the Alliance for Aging Research responded to the U.S. House Energy and Commerce Committee 21st Century Cures Initiative and its recently released discussion draft.
February 10, 2015

21st Century Cures Feedback Letter

The Alliance for Aging Research submitted a feedback letter on the 21st Century Cures discussion draft released on January 27, 2015 to Chairman Upton and Ranking Member DeGette.
February 10, 2015

ACT-AD 21st Century Cures Letter

Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) submitted a letter the House Committee on Energy and Commerce to provide feedback on the 21st Century Cures discussion draft released on January 27, 2015.    
December 15, 2014

Exploring Scientific Evaluation and Intake Recommendations of Bioactive Compounds and the Public/Private Path to Get There – Meeting Summary

On October 23, 2014, the Alliance for Aging Research, with support from Mars, Inc., convened key stakeholders from the Institute of Medicine (IOM) and other non-profit organizations, the U.S. and Canadian Governments, academia, and private industry to discuss scientific evaluation of bioactive compounds. Dr. Joanne Lupton, Distinguished Professor of Nutrition at Texas A&M University, co-chaired the meeting with Susan Peschin, President and CEO of the Alliance for Aging Research, and described the goals of the meeting as follows: (1) to identify concrete ideas for creating an evaluation process for bioactives, including intake recommendations, and (2) to address issues with and opportunities for public-private partnerships. She also shared a working definition of bioactive compounds and suggested it be used for the discussion: Bioactives, according to the working definition, are “constituents in foods or dietary supplements, other than those needed to meet basic human needs, which are responsible for changes in health status.” The meeting included four presentations that helped frame the discussion. These presentations were on perspectives from the Subcommittee on Dietary Reference Intakes (DRIs), application of the DRI paradigm to bioactives, lessons learned from research on cocoa flavanols, and development of public-private partnerships. Download the full meeting summary to learn more.